Floatz logo

Defactinib

Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

Lei ZhengSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

283 Active assets in the Resectable Pancreatic Ductal Adenocarcinoma (PDAC) cohort.

Asset / SponsorPhaseRating
Irinotecan
NRG Oncology
Phase 3BB
Rmc-6236
Tango Therapeutics, Inc.
Phase 3BB
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER
OHSU Knight Cancer Institute
Phase 2BB
Daraxonrasib
Revolution Medicines, Inc.
Phase 3BB
S-1
Genentech, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

Defactinib is also rated in:

ovarian serous adenocarcinomaDormant
BB
Indicative ·
68 / 100
View asset →
KRAS Activating MutationDormant
BB
Indicative ·
64 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →